Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.36 |
| ▸ | SELL | P14151 | 1/20 | 0.36 |
| ▸ | SELP | P16109 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14925198 | 1.00 | CD69 (0.44) | CD69LGALS3LGALS8LGALS4MAPK1 | |
| SCHEMBL17131368 | 1.00 | CD69 (0.44) | CD69LGALS3LGALS8LGALS4MAPK1 | |
| SCHEMBL18022304 | 0.90 | CD69 (0.47) | CD69LGALS3LGALS8LGALS4MAPK1 | |
| SCHEMBL23491004 | 0.89 | CD69 (0.49) | CD69LGALS3LGALS8LGALS4MAPK1 | |
| SCHEMBL13895616 | 0.89 | CD69 (0.49) | CD69LGALS3LGALS8LGALS4MAPK1 | |
| SCHEMBL2602688 | 0.83 | LGALS3 (0.49) | CD69LGALS3LGALS8LGALS4MAPK1 | |
| SCHEMBL14091725 | 0.82 | LGALS3 (0.47) | CD69LGALS3LGALS8LGALS4MAPK1 | |
| SCHEMBL18589695 | 0.82 | LGALS3 (0.47) | CD69LGALS3LGALS8LGALS4MAPK1 | |
| SCHEMBL16745289 | 0.82 | MAPK1 (0.41) | CD69LGALS3LGALS8LGALS4MAPK1 | |
| SCHEMBL12694356 | 0.81 | LGALS3 (0.58) | CD69LGALS3LGALS8LGALS4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039447-B2 | Derivatives of hyaluronic acid, their preparation process and their uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2011-10-18 | — | — | US | disclosed |
| US-20080306023-A1 | Derivatives of Hyaluronic Acid, Their Preparation Process and Their Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306023-A1 | Derivatives of Hyaluronic Acid, Their Preparation Process and Their Uses | CD44, F12, F11 | CD69 1600/4885LGALS3 553/4885LGALS8 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.